PD-L1/miR-155 Interplay in Pediatric High-Grade Glioma.
Jakub LitakWieslawa GrajkowskaJacek BoguckiPaweł KowalczykAlicja PetniakArkadiusz PodkowińskiJustyna SzumiłoJanusz KockiJacek RolińskiMansur Rahnama-HezavahMarcin RoszkowskiCezary GrochowskiPublished in: Brain sciences (2022)
High-grade pediatric glioma (p-HGG-WHO 2021, formerly GBM-WHO 2016), as a common, aggressive, and highly lethal primary brain malignancy in adults, accounts for only 3-15% of primary brain tumors in pediatric patients. After leukemia, brain malignancies are the second most common in the pediatric population and first in incidences concerning solid tumors. This study was designed on the basis of 14 pediatric patients hospitalized at Children's Memorial Health Institute in Warsaw, Poland, due to p-HGG treatment. All the patients had a histopathological diagnosis performed by an experienced neuropathologist according to WHO guidelines (WHO 2016 Grade IV Glioblastoma). A significant correlation was found between the miR-155 concentration and the level of PD-L1 expression in p-HGG tumor tissue. Very few reports have indicated PD-L1 expression in pediatric patients.
Keyphrases
- high grade
- cell proliferation
- low grade
- long non coding rna
- end stage renal disease
- resting state
- long noncoding rna
- white matter
- healthcare
- chronic kidney disease
- newly diagnosed
- public health
- ejection fraction
- mental health
- young adults
- bone marrow
- prognostic factors
- functional connectivity
- emergency department
- multiple sclerosis
- cerebral ischemia
- health information
- social media
- climate change
- blood brain barrier